Skip to main
HRMY
HRMY logo

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harmony Biosciences Holdings Inc. is positioned as a compelling growth story in the neurology sector, supported by ongoing registrational trials and the sustained commercial success of its flagship product, WAKIX. The company benefits from a strong financial foundation, providing the necessary resources for both internal research and development as well as potential business development opportunities. Despite the setback with ZYN002, the company maintains a positive outlook due to its consistent commercial execution and a robust pipeline of drug candidates that continue to advance.

Bears say

Harmony Biosciences Holdings Inc.'s outlook appears negative primarily due to the failure of its pivotal Phase 3 RECONNECT trial for ZYN002, which did not meet its primary endpoint, reflecting a higher-than-expected placebo response that diluted the drug's treatment efficacy. This setback is significant, as the trial's outcome raises concerns about the product's potential in a critical market segment, specifically for patients with Fragile X syndrome who exhibit substantial unmet medical needs. The reliance on a single product for revenue generation also accentuates the risks associated with further pipeline developments, given the challenges faced in clinical evaluations.

HRMY has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Strong Buy based on their latest research and market trends.

According to 8 analysts, HRMY has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.